Pharmaceuticals
Kuching to Host Asia's Leading Diabetes Experts at "Diabetes Asia 2026" Conference (DAC 2026)
KUCHING, Malaysia, July 30, 2026 /PRNewswire/ -- As diabetes continues to place an increasing burden on Malaysia's healthcare system — affecting an estimated 4.75 million Malaysian adults - Kuching will become the regional meeting point for leading diabetes experts this October as it hosts the "D...
2026-07-30 22:15
3099
NIPRO CORPORATION Receives FDA 510(k) Clearance for ELISIO™-HX, Introducing HDs to the United States
New medium-cutoff Dialyzer with a Super High-flux membrane brings NIPRO's approach to expanded hemodialysis to United States healthcare providers. OSAKA, Japan, July 30, 2026 /PRNewswire/ -- NIPRO CORPORATION has been granted 510(k) clearance for the ELISIO-HX dialyzer by the United States Food ...
2026-07-30 20:10
2171
Continuity Biosciences Appoints Vicky Papoutsis to Board of Directors
Business development and corporate strategy executive joins Board as Company advances its clinical programs and partnering activity BRADENTON, Fla., July 30, 2026 /PRNewswire/ -- Continuity Biosciences today announced the appointment of Vicky Papoutsis to its Board of Directors. Vicky brings mor...
2026-07-30 20:00
1462
NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
CHENGDU, China, July 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan...
2026-07-30 17:19
2109
Fosun International Issues Positive Profit Alert: Profit Attributable to Owners of the Parent for 1H2026 Expected to be Approx. RMB 1.5 Billion to RMB1.8 Billion
HONG KONG, July 29, 2026 /PRNewswire/ -- On 29th July, Fosun International (00656.HK) issued a positive profit alert. Its profit attributable to owners of the parent for the first half of 2026 is expected to range from approximately RMB1.5 billion to RMB1.8 billion representing an increase of app...
2026-07-29 17:35
3899
AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer
* ELAHERE is the first and only antibody-drug conjugate (ADC) therapy approved specifically for patients with folate receptor alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, who have received one to three prior s...
2026-07-29 10:00
2516
IHH Healthcare Expands 'IHH Catalyst' to North Asia to Accelerate Clinical Adoption of Healthcare Innovation
Building on the success of its inaugural programme in India, IHH Healthcare is launching IHH Catalyst | North Asia Edition to help startups in Hong Kong, Chinese Mainland and neighbouring markets turn healthcare innovation into real-world clinical impact. HONG KONG and SINGAPORE and KUALA L...
2026-07-28 18:44
1593
Everest Medicines Announces Participation in Upcoming Investor Conferences
SHANGHAI, July 27, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Fi...
2026-07-27 23:17
2385
Seegene Proposes Comprehensive Reproductive Tract Infection Testing Approach through the Global Million Clinical Study (GMCS)
* STAgora™ analysis of approximately 60,000 test results collected over 42 months showed that STI pathogens were detected in 82% of HPV-positive cases * Findings support the potential value of a comprehensive testing approach that provides both HPV and STI pathogen information * Seegene to v...
2026-07-27 21:00
6424
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
TAIPEI, July 27, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics,today reaffirmed its strategic focus on pursuing global li...
2026-07-27 20:20
2309
Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
* Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. * Offers 5x greater sensitivity vs. in-class instruments with lower detection limits in smaller sample volum...
2026-07-27 20:10
2698
Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
CHENGDU, China, July 27, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)...
2026-07-27 19:40
2533
Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model. -Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will be submitted to the U.S. Food and Drug Administration (FDA...
2026-07-27 18:42
2902
Jiangxi Bio's Veterinary Tetanus Antitoxin Production Line Officially Commenced Production,Accelerating Commercialization of the Animal Antiserum Portfolio
HONG KONG, July 27, 2026 /PRNewswire/ -- Jiangxi Institute of Biological Products Inc. and its subsidiaries (collectively, "Jiangxi Bio" or the "Group") (stock code: 6915.HK) is pleased to announce that the veterinary tetanus antitoxin ("Veterinary TAT") production line of Chifeng Bo-en Pharmaceu...
2026-07-27 15:36
4547
IHH Healthcare Expands 'IHH Catalyst' to North Asia to Accelerate Clinical Adoption of Healthcare Innovation
Building on the success of its inaugural programme in India, IHH Healthcare is launching IHH Catalyst | North Asia Edition to help startups in Hong Kong, Chinese Mainland and neighbouring markets turn healthcare innovation into real-world clinical impact. HONG KONG and SINGAPORE and KUALA L...
2026-07-27 11:00
1690
Seaweed extract shown to relieve prostate symptoms
In a breakthrough clinical trial undertaken by Australian biotechnology company Marinova, a unique seaweed extract has been shown to relieve the symptoms of benign prostatic hyperplasia (BPH). HOBART, Australia, July 27, 2026 /PRNewswire/ -- A randomised, double-blind, placebo-controlled clinical...
2026-07-27 07:00
1414
Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company's Phase 2b/3 clinical trial of i...
2026-07-24 09:30
2089
ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406
SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate (AFC) drug for influenza prophylaxis. The clini...
2026-07-24 09:00
2318
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
- Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight loss compared to eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model. HONG KONG, July 23, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ...
2026-07-23 08:10
3227
Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive results fro...
2026-07-22 20:28
4004
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 314 media titles]
2026-08-27 10:25
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 300 media titles]
2026-09-01 11:00
RHINOSHIELD AirX Sets GUINNESS WORLD RECORDS™ Title in Record-Breaking Near-Space Drop Challenge
[Picked up by 288 media titles]
2026-08-26 16:08
ViewSonic Launches XG2738-2K-OLED Gaming Monitor with QD-OLED Technology and OLED Care
[Picked up by 288 media titles]
2026-08-27 10:30
Most Read
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
16061